Navmeda - Company finances
|
EUR
|
2021
From: 2021-11-25
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | 500 | 33,126 | 88,574 | 92,329 | 52,050 |
| Profit before tax | 489 | 19,678 | 49,227 | 59,565 | 30,051 |
| Net profit | 489 | 18,693 | 46,766 | 56,587 | 28,248 |
| Equity | 2,489 | 21,182 | 48,948 | 58,775 | 30,436 |
| Liabilities | - | 5,522 | 6,789 | 10,078 | 39,652 |
| Non-current assets | 0 | 1,164 | 765 | 1,792 | 714 |
| Current assets | 2,489 | 25,540 | 54,972 | 67,061 | 69,374 |
| Total assets | 2,489 | 26,704 | 55,737 | 68,853 | 70,088 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 7,825 | 9,475 | 14,199 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | +6525.2% | +167.4% | +4.2% | -43.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 19.6% | 70.0% | 83.9% | 82.2% | 40.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 19.6% | 88.2% | 95.5% | 96.3% | 92.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 97.8% | 56.4% | 52.8% | 61.3% | 54.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 97.8% | 59.4% | 55.6% | 64.5% | 57.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 0.3 | 0.1 | 0.2 | 1.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Navmeda - Social security debts
The company had no debts to Sodra
Navmeda - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-02-26 | 2025-03-12 | 4970.06 |
| 2025-02-25 | 2025-02-25 | 5016.06 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Navmeda, MB (code 305942799) is a Lithuanian small partnership engaged in retail sale of other medical and orthopaedic goods. In 2025, the company generated €52.0K in revenue and €28.2K in net profit, which resulted in a profit margin of 54.3%. Revenue declined by 43.6% year on year and by 41.2% over two years, after reaching €88.6K in 2023 and €92.3K in 2024. Despite the lower turnover in 2025, profitability remained strong relative to sales. The balance sheet expanded slightly to €70.1K in total assets, compared with €68.9K in 2024 and €55.7K in 2023. Equity decreased to €30.4K from €58.8K a year earlier, while liabilities rose to €39.7K from €10.1K. The equity ratio stood at 43.4% and debt-to-equity at 1.30. Return on equity was 92.8% and return on assets 40.3%, supported by an asset turnover of 0.74x. Short-term assets made up almost all assets, at €69.4K in 2025.